Chemo-Free hope: new drug duo targets tough lung cancer

NCT ID NCT06865339

Recruiting now Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing whether combining two immunotherapy drugs (cemiplimab and fianlimab) with radiation can shrink tumors in people with locally advanced non-small cell lung cancer who haven't had treatment yet. The study will enroll 76 participants and measure how well the tumors respond using PET scans. The goal is to find a more effective, chemotherapy-free option for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cemiplimab and fianlimab (immunotherapy drugs) plus radiation
What this could lead to: If successful, this could offer a chemotherapy-free treatment option for locally advanced lung cancer, potentially improving response rates and long-term outcomes.
What could go wrong: This is an early Phase 2 trial with only 76 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like lung inflammation or colitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED NSCLC

Contacts and locations

Locations

Montefiore Einstein Comprehensive Cancer Center (MECCC)
RECRUITING

The Bronx, New York, 10461, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.